Treatment Information

Cancer Monthly > Treatment Information
Back

Breast Cancer treatment details. Chemotherapy.

Baylor Charles A. Sammons Cancer Center, Dallas, TX, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Dallas, TX
Treatments:ChemotherapyHospital:Baylor Charles A. Sammons Cancer Center
Drugs:Journal:Link
Date:Jan 2011

Description:

Patients:
This study involved women with triple-negative metastatic breast cancer, which is type of cancer that does not have estrogen receptor (ER-), progesterone receptor (PR-), or an abundance of the human epidermal growth factor receptor 2 (HER-2). Patients were divided into 2 treatment groups. Group A had 61 patients with a median age of 56 years. Group B had 62 patients with a median age of 53 years.

Treatment:
Group A: Patients were given the chemotherapy agents gemcitabine and carboplatin, as well as the biologic therapy agent iniparib (an inhibitor of a DNA damage repair protein called PARP1, therefore leading to cancer cell death).

Group B: Patients were treated with the chemotherapy agents gemcitabine and carboplatin only.

Toxicities:
There were 5 deaths in this study (3 in group A, 2 in group B) that were reported as “fatal adverse events attributable to disease progression.” Grade 4 thrombocytopenia and neutropenia, as well as grade 3 anemia and fatigue were reported.

Results:
Group A: Median progression-free survival was 5.9 months and the median overall survival was 12.3 months.
Group B: Median progression-free survival was 3.6 months and the median overall survival was 7.7 months.

Support:
This study was supported by BiPar Sciences (owned by Sanofi Aventis), makers of iniparib.

Correspondence: Dr. Joyce O’Shaughnessy; email: [email protected]

Email Physician More Information


Back